Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

5 clinical trials · Sponsor

Record	Firm	Date
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) (NCT02303782)	Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2015-01-01
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) (NCT02296476)	Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2014-10-29
A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114)	Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2014-10-23
A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) (NCT01713582)	Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2012-12-14
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors (NCT01724320)	Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2012-02-01

Every clearance here is in the API, with alerts when new ones post.